Immunize.org supports evidence-based vaccination recommendations and schedules. Read more at About Us.

Ask the Experts: RSV (Respiratory Syncytial Virus): Contraindications & Precautions (Vaccines and Antibody)

Results (2)

Nirsevimab (Beyfortus, Sanofi) and clesrovimab (Enflonsia, Merck) are contraindicated in persons with a history of severe allergic reactions (e.g., anaphylaxis) after a previous dose of the same product or to a product component. As with any injection, when administering nirsevimab or clesrovimab to children with increased risk for bleeding, providers should follow CDC’s general best practices for immunization of children with bleeding disorders: www.cdc.gov/vaccines/hcp/imz-best-practices/special-situations.html#cdc_report_pub_study_section_8-vaccinating-persons-with-increased-bleeding-risk.

Nirsevimab or clesrovimab administration should be deferred if a child has a moderate or severe acute illness until they have recovered. A mild illness is not a reason to delay an otherwise indicated dose.

Last reviewed: November 8, 2026

RSV vaccines are contraindicated for and should not be administered to people with a history of severe allergic reaction, such as anaphylaxis, to any component of the vaccine. People experiencing moderate or severe acute illness with or without fever should delay RSV vaccination until they are improved, as a precaution.

Last reviewed: November 8, 2026

This page was updated on .